pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$ILMNILLUMINA, INC.

$ILMN213.24+4.02%
San Diego, CA, USupdated 10h ago

Illumina, Inc. is an American biotechnology company, headquartered in San Diego, California. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serves the sequencing, genotyping and gene expression, and proteomics markets, and serves more than 155 countries.

Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes

🐶 often sniffed alongside

top 5
  • tagOncology2 co-mentions · 2 sources
  • tagCAR-T2 co-mentions · 1 sources
  • tagAdCom2 co-mentions · 2 sources
  • tagPMA Approval2 co-mentions · 2 sources
  • tagRecall1 co-mentions · 1 sources
pipeline
0
marketed
0
phase 3
0
catalysts ytd
2
approvals ytd
0
recalls ytd
0

Pipeline(0)

no pipeline products on record

📅 Upcoming

Oct 29, 2026
earnings
$ILMN213.24+4.02%
in 2mo
ILLUMINA, INC. earnings
ILLUMINA, INC.
→

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • —NeuroSeq: A Prospective Trial to Evaluate the Diagnostic Yield of Whole Genome Sequencing (WGS) in Adult Neurologycompletedn=160
  • —iKnow: A Prospective Study to Evaluate the Use of Multi-omics in Multi-System, Early Onset Disordersactive not recruitingn=150
  • N/ACardioSeq: Impact of WGS in Individuals With CVDactive not recruitingn=1,500

Insider activity

source: SEC Form 4
routine RSU / option mechanics (6)
  • Mar 31, 26grantUllem Scott B. · director190 sh
  • Mar 31, 26grantMeister Keith A. · director161 sh
  • Mar 5, 26grantThaysen Jacob · Chief Executive Officer30,022 sh
  • Mar 5, 26grantThaysen Jacob · Chief Executive Officer30,022 sh
  • Mar 5, 26grantThaysen Jacob · Chief Executive Officer25,734 sh
  • Mar 5, 26grantDhingra Ankur · SVP, Chief Financial Officer10,918 sh
🐶 Hiring Signal
next earnings Oct 29, 2026
No open roles indexed yet — view ILLUMINA, INC. jobs →

News

no news has mentioned this company yet
identifiers
ticker
$ILMN
SEC CIK
0001110803
country
US
source
sec_tickers
mentioned in
0news items
entity-linker matched
Data sources
SEC EDGAR · openFDA
last refreshed 21m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?